Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell
CEO James McDonnell, held a shareholder briefing with Reach Markets.
In this session, James discussed:
- Why the First Patient Dosed marks a significant milestone in the commencement of the PTX-100 Phase 2a study, bringing a potential treatment one step closer to a current unmet need.
- How the FDA’s Fast Track and Orphan Drug Designations could lead to accelerated approval for PTX-100 and progress commercialisation – with a A$1bn+ market in the US alone.
- Why PTX-100 is just one application of Prescient’s much broader RAS Family inhibitor technology, which has potential applications for 22% of cancer cases world-wide.
Recorded on 29th May 2025 at 12pm (AEST)
Featured Speaker
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company’s acquistion by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
